Details of the Drug

General Information of Drug (ID: DMWLC57)

Drug Name
Brentuximab vedotin
Synonyms Adcetris (TN)
Indication
Disease Entry ICD 11 Status REF
Hodgkin lymphoma 2B30 Approved [1]
Classic Hodgkin lymphoma N.A. Investigative [2]
Drug Type
Monoclonal antibody
ADMET Property
Elimination
About 24% of the total MMAE ingested as part of the ADC during an ADCETRIS infusion was recovered in both urine and feces over a 7-day time frame []
Half-life
The concentration or amount of drug in body reduced by one-half in 4 - 6 days []
Metabolism
The drug is metabolized via oxidation by CYP3A4/5 []
Cross-matching ID
DrugBank ID
DB08870
TTD ID
D03TIS
INTEDE ID
DR0225
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Lymphocyte activation antigen CD30 (TNFRSF8) TT2GM5R TNR8_HUMAN Modulator [3]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Brentuximab vedotin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [5]
Sarecycline DMLZNIQ Moderate Decreased clearance of Brentuximab vedotin due to the transporter inhibition by Sarecycline . Acne vulgaris [ED80] [6]
Tagraxofusp DM9HQ5U Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Tagraxofusp. Acute myeloid leukaemia [2A60] [6]
Gilteritinib DMTI0ZO Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Gilteritinib. Acute myeloid leukaemia [2A60] [6]
Inotersen DMJ93CT Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Inotersen. Amyloidosis [5D00] [6]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [7]
Troleandomycin DMUZNIG Moderate Decreased clearance of Brentuximab vedotin due to the transporter inhibition by Troleandomycin. Bacterial infection [1A00-1C4Z] [8]
Erdafitinib DMI782S Moderate Decreased clearance of Brentuximab vedotin due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [9]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [10]
Eribulin DM1DX4Q Moderate Increased risk of peripheral neuropathy by the combination of Brentuximab vedotin and Eribulin. Breast cancer [2C60-2C6Y] [11]
HKI-272 DM6QOVN Moderate Decreased clearance of Brentuximab vedotin due to the transporter inhibition by HKI-272. Breast cancer [2C60-2C6Y] [6]
LY2835219 DM93VBZ Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and LY2835219. Breast cancer [2C60-2C6Y] [6]
Tucatinib DMBESUA Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Tucatinib. Breast cancer [2C60-2C6Y] [8]
Alpelisib DMEXMYK Moderate Decreased clearance of Brentuximab vedotin due to the transporter inhibition by Alpelisib. Breast cancer [2C60-2C6Y] [6]
Fenofibric acid DMGO2MC Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Fenofibric acid. Cardiovascular disease [BA00-BE2Z] [6]
Macitentan DMP79A1 Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Macitentan. Cardiovascular disease [BA00-BE2Z] [6]
Regorafenib DMHSY1I Moderate Decreased clearance of Brentuximab vedotin due to the transporter inhibition by Regorafenib. Colorectal cancer [2B91] [8]
Intedanib DMSTA36 Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Intedanib. Colorectal cancer [2B91] [6]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Cannabidiol. Epileptic encephalopathy [8A62] [12]
Boceprevir DMBSHMF Moderate Decreased metabolism of Brentuximab vedotin caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [12]
Daclatasvir DMSFK9V Moderate Decreased clearance of Brentuximab vedotin due to the transporter inhibition by Daclatasvir. Hepatitis virus infection [1E50-1E51] [6]
177Lu-DOTATATE DMT8GVU Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [6]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Brentuximab vedotin caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [12]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [13]
Givosiran DM5PFIJ Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [6]
Brigatinib DM7W94S Moderate Decreased clearance of Brentuximab vedotin due to the transporter inhibition by Brigatinib. Lung cancer [2C25] [8]
Lurbinectedin DMEFRTZ Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Lurbinectedin. Lung cancer [2C25] [6]
PF-06463922 DMKM7EW Moderate Increased metabolism of Brentuximab vedotin caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [12]
Alectinib DMP1I6Y Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Alectinib. Lung cancer [2C25] [6]
BIBW 2992 DMTKD7Q Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and BIBW 2992. Lung cancer [2C25] [6]
Pralsetinib DMWU0I2 Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Pralsetinib. Lung cancer [2C25] [6]
Capmatinib DMYCXKL Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Capmatinib. Lung cancer [2C25] [8]
Selpercatinib DMZR15V Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Selpercatinib. Lung cancer [2C25] [6]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [6]
IPI-145 DMWA24P Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and IPI-145. Mature B-cell leukaemia [2A82] [6]
Blinatumomab DMGECIJ Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Blinatumomab. Mature B-cell lymphoma [2A85] [6]
Ponatinib DMYGJQO Moderate Decreased clearance of Brentuximab vedotin due to the transporter inhibition by Ponatinib. Mature B-cell lymphoma [2A85] [8]
Arry-162 DM1P6FR Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Arry-162. Melanoma [2C30] [6]
Vemurafenib DM62UG5 Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Vemurafenib. Melanoma [2C30] [8]
Lasmiditan DMXLVDT Moderate Decreased clearance of Brentuximab vedotin due to the transporter inhibition by Lasmiditan. Migraine [8A80] [14]
Carfilzomib DM48K0X Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Carfilzomib. Multiple myeloma [2A83] [15]
Tecfidera DM2OVDT Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Tecfidera. Multiple sclerosis [8A40] [6]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Brentuximab vedotin and Siponimod. Multiple sclerosis [8A40] [16]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Brentuximab vedotin and Ocrelizumab. Multiple sclerosis [8A40] [17]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Brentuximab vedotin and Ozanimod. Multiple sclerosis [8A40] [12]
Rolapitant DM8XP26 Moderate Decreased clearance of Brentuximab vedotin due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [6]
Entrectinib DMMPTLH Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Entrectinib. Non-small cell lung cancer [2C25] [6]
Istradefylline DM20VSK Moderate Decreased clearance of Brentuximab vedotin due to the transporter inhibition by Istradefylline. Parkinsonism [8A00] [6]
Abametapir DM2RX0I Moderate Decreased metabolism of Brentuximab vedotin caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [18]
Lefamulin DME6G97 Moderate Decreased metabolism of Brentuximab vedotin caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [19]
Enzalutamide DMGL19D Moderate Increased metabolism of Brentuximab vedotin caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [20]
Sarilumab DMOGNXY Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Sarilumab. Rheumatoid arthritis [FA20] [6]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Brentuximab vedotin when combined with Anthrax vaccine. Sepsis [1G40-1G41] [21]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Brentuximab vedotin caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [12]
Larotrectinib DM26CQR Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [6]
LEE011 DMMX75K Moderate Decreased clearance of Brentuximab vedotin due to the transporter inhibition by LEE011. Solid tumour/cancer [2A00-2F9Z] [8]
Pomalidomide DMTGBAX Moderate Increased risk of peripheral neuropathy by the combination of Brentuximab vedotin and Pomalidomide. Systemic sclerosis [4A42] [11]
Fostamatinib DM6AUHV Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Fostamatinib. Thrombocytopenia [3B64] [6]
Lenvatinib DMB1IU4 Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Lenvatinib. Thyroid cancer [2D10] [6]
Cabozantinib DMIYDT4 Moderate Decreased clearance of Brentuximab vedotin due to the transporter inhibition by Cabozantinib. Thyroid cancer [2D10] [6]
Elagolix DMB2C0E Moderate Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Elagolix. Uterine fibroid [2E86] [6]
Secnidazole DMJ18YL Moderate Increased risk of peripheral neuropathy by the combination of Brentuximab vedotin and Secnidazole. Vaginal discharge [MF3A] [11]
⏷ Show the Full List of 62 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6772).
2 Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults. Blood. 2023 Apr 27;141(17):2075-2084.
3 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
4 Brentuximab vedotin.
5 European Medicines Agency "Summary on compassionate use. Remdesivir Gilead.".
6 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
7 Product Information. Hivid (zalcitabine). Roche Laboratories, Nutley, NJ.
8 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
9 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
10 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
11 Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
12 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
13 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
14 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
15 Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
16 Cerner Multum, Inc. "Australian Product Information.".
17 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
18 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
19 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
20 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
21 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]